Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.

Diabetologia - 1 Mar 2003

Standl E, Füchtenbusch M

Abstract excerpt

Evidence obtained in the 1990's strongly supports the notion that glycaemic control is important not only in Type I (insulin-dependent), but also in Type II (non-insulin-dependent) diabetes mellitus. Although measurement of HbA(1c) is the standard for assessing the effect of glucose control in the occurrence and prevention of diabetic sequelae, more recent evidence indicates that other glucose parameters are also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Drug Therapy, Combination
Share to Fasting

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hyperglycemia

Share to Hypoglycemic Agents

Share to Insulin Resistance

Share to Insulin Secretion

Source

Identifiers

PMID: 12652356
DOI: 10.1007/s00125-002-0934-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.PMID 12652356Read ↗

A review of nateglinide in the management of patients with type 2 diabetes.Semantic proximity Read ↗

A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated ComorbiditiesSemantic proximity Read ↗

Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.Semantic proximity Read ↗

Intervention therapies for insulin-dependent diabetes.Semantic proximity Read ↗

What is the best management strategy for patients with severe insulin resistance?Semantic proximity Read ↗

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.Semantic proximity Read ↗

Recommendations for insulin initiation based on ethnicity.Semantic proximity Read ↗

A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationSemantic proximity Read ↗

First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and SafetySemantic proximity Read ↗

Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients.Semantic proximity Read ↗

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.Semantic proximity Read ↗

Modern Hypoglycemic Agents and Their Perioperative ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.